MA44631A - Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 - Google Patents

Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6

Info

Publication number
MA44631A
MA44631A MA044631A MA44631A MA44631A MA 44631 A MA44631 A MA 44631A MA 044631 A MA044631 A MA 044631A MA 44631 A MA44631 A MA 44631A MA 44631 A MA44631 A MA 44631A
Authority
MA
Morocco
Prior art keywords
depression
receiver
agents
link
treatment
Prior art date
Application number
MA044631A
Other languages
English (en)
French (fr)
Inventor
Guang Chen
Yu Sun
Dai Wang
Gayle Wittenberg
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA44631A publication Critical patent/MA44631A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA044631A 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 MA44631A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319558P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
MA44631A true MA44631A (fr) 2019-02-13

Family

ID=59998986

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044631A MA44631A (fr) 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6

Country Status (7)

Country Link
US (1) US20170291942A1 (https=)
EP (1) EP3440108A4 (https=)
JP (1) JP2019519470A (https=)
AU (1) AU2017248280A1 (https=)
CA (1) CA3019828A1 (https=)
MA (1) MA44631A (https=)
WO (1) WO2017177032A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523138A (ja) * 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
JP6347477B2 (ja) * 2013-12-27 2018-06-27 国立大学法人千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Also Published As

Publication number Publication date
US20170291942A1 (en) 2017-10-12
WO2017177032A3 (en) 2017-11-16
WO2017177032A2 (en) 2017-10-12
AU2017248280A1 (en) 2018-10-25
EP3440108A2 (en) 2019-02-13
EP3440108A4 (en) 2020-01-08
JP2019519470A (ja) 2019-07-11
CA3019828A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
EP3811971A4 (en) ANTIBODIES FOR BLOCKING THE INTERACTION OF CD47-SIRPA AND ITS USES
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3765960A4 (en) EVENT STREAM PROCESSING
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA49990A (fr) Récepteurs de liaison à l'antigène améliorés
EP3334484A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING HYPOXIA OR HYPOXIA RESPONSE FOR THE TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STEM DISEASES
MA45036A (fr) Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
EP3515944A4 (en) METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3600434A4 (en) TREATMENT OF PULMONAL HYPERTENSION
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3325963A4 (en) INCREASE OF BLOOD CELL ESTIMATION
EP3820888A4 (en) CO-RECEPTOR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASES
EP3630102A4 (en) FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER
EP3506943A4 (en) METHOD AND COMPOSITIONS WITH INTERLEUKIN 6 RECEPTOR ALPHA BINDING SINGLE CHAIN VARIABLE FRAGMENTS
SI3464266T1 (sl) Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
EP3474863A4 (en) PHOSPHORAMIDATE FOR TREATING THE HEPATITIS C VIRUS
EP3355889A4 (en) DIAMINOPYRIMIDINE P2X3 AND P2X2 / 3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF HUSTEN
EP3723657A4 (en) SUSPENSION CLEANING
EP3403675A4 (en) ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA
EP3522912A4 (en) HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
MA51157A (fr) Récepteurs de l'interleukine darique
EP3612214A4 (en) ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
EP3265115A4 (en) USE OF A PTHRP ANALOGUE TO REDUCE FRACTURE RISK
EP3863673A4 (en) TREATMENT WITH HIGHLY SILYLATED IGG COMPOSITIONS
EP3285789A4 (en) PLANT EXTRACTS FOR THE TREATMENT OF OVERWEIGHT AND ADIPOSITAS